Revvity shares surged roughly 8% in the session following management’s announcement that the company will exceed its full-year 2025 adjusted EPS guidance. Analysts remain divided, with 12 upgrading their ratings over the past month while 10 have maintained a cautious stance. The consensus price target sits within 3% of the current trading level, underscoring the stock’s pivotal position. Institutional ownership stands at 78%, suggesting that any further directional move could trigger significant repositioning by large funds.

In its update, Revvity said it now expects adjusted earnings per share for the full year 2025 to top the previously guided range of $4.90 to $5.00. Management attributed the upward revision to sustained demand for contract research and diagnostics services, particularly in translational multi-omics and imaging. This marks a notable improvement from the $4.75 mid-point implied by earlier guidance issued in October 2025.

Revvity provided preliminary fourth-quarter revenue of approximately $772 million, reflecting 6% reported and 4% organic growth versus the year-ago period. For the full year 2025, reported revenue is expected to reach roughly $2.855 billion—up 4% on a reported basis and 3% on an organic basis. The fourth-quarter margin profile is anticipated to benefit from higher utilization in the diagnostics segment and tight cost control in R&D, with non-GAAP operating profit margin projected near 22%.

Revvity announced a collaboration with Eli Lilly to integrate its TuneLab AI models into Lilly’s Signals Xynthetica platform. The alliance will deploy secure, federated learning techniques across preclinical data sets to accelerate target identification and reduce time-to-lead. The companies aim to process over 1.2 billion data points annually and expect to initiate the first joint validation study by mid-2026, with potential to extend the approach to biomarker discovery and translational analytics.